Lapatinib (also known as Lapatinib Ditosylate, Lapatinib base, GSK572016, GW 572016, Tyverb) is a selective inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases for the treatment of breast cancer, especially metastatic breast cancer that has progressed after trastuzumab treatment and other chemotherapy.
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.